CLBS - カラドリアス・バイオサイエンス （Caladrius Biosciences Inc.）

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA”

BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will participate in the following investor events:

Study to be part of Roche''s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius'' initial investment in Cend BASKING RIDGE, N.J. and SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ: CLBS ) ("Caladrius" or the "Company") and Cend Therapeutics, Inc. ("Cend"), today announced Cend''s execution of a collaboration agreement with F. Hoffmann-La Roche Ltd. ("Roche") to evaluate Cend''s lead investigational drug, CEND-1, in combination with atezolizumab (Tecentriq ® ), Roche''s PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma ("mPDAC"). Under the terms of the agreement, Roche will be responsible for operational management of the trial while Cend and Roche share equally in the costs of the CEND-1 treatment arms in the study. "We are extremely pleased to work with Roche, a global leader in oncology, to explore the potential of CEND-1 in combination with chemotherapy and immunotherapy for the treatment of pancreatic cancer," stated David Slack, Chief Executive Officer of Cend. "We are committed to exploring applications of CEND-1 to improve clinical outcomes for patients with this deadly disease.

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA”

BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will participate in the following investor events:

Study to be part of Roche''s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius'' initial investment in Cend BASKING RIDGE, N.J. and SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ: CLBS ) ("Caladrius" or the "Company") and Cend Therapeutics, Inc. ("Cend"), today announced Cend''s execution of a collaboration agreement with F. Hoffmann-La Roche Ltd. ("Roche") to evaluate Cend''s lead investigational drug, CEND-1, in combination with atezolizumab (Tecentriq ® ), Roche''s PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma ("mPDAC"). Under the terms of the agreement, Roche will be responsible for operational management of the trial while Cend and Roche share equally in the costs of the CEND-1 treatment arms in the study. "We are extremely pleased to work with Roche, a global leader in oncology, to explore the potential of CEND-1 in combination with chemotherapy and immunotherapy for the treatment of pancreatic cancer," stated David Slack, Chief Executive Officer of Cend. "We are committed to exploring applications of CEND-1 to improve clinical outcomes for patients with this deadly disease.

Caladrius Biosciences, Inc. (NASDAQ:NASDAQ:CLBS) Q2 2022 Results Conference Call August 04, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David…

Peer-reviewed study data suggest CEND-1, in combination with gemcitabine and nab-paclitaxel, demonstrates favorable safety and tolerability along with encouraging efficacy Peer-reviewed study data suggest CEND-1, in combination with gemcitabine and nab-paclitaxel, demonstrates favorable safety and tolerability along with encouraging efficacy

BASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the BIO International Convention being held in-person at the San Diego Convention Center in San Diego, CA, from June 13-16, 2022.

Equities research analysts expect Caladrius Biosciences, Inc. to report earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have…

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus INmune Bio Planned Midstage Alzheimer''s Trial Put On FDA Hold The FDA has requested additional information on the Chemistry Manufacturing and Controls of the newly manufactured INmune Bio Inc''s (NASDAQ: INMB ) XPro1595. As part of the communication, the FDA placed the company''s Investigational New Drug application for the Phase 2 trial of XPro in Alzheimer''s Disease on clinical hold. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro remains open in Australia and continues to enroll patients. Shares are down 27.2% at $5.29 during the premarket session. Caladrius Biosciences Stops Enrollment In Midstage Heart Disease Study Caladrius Biosciences Inc (NASDAQ: CLBS ) suspended patient enrollment in its Phase 2b FREEDOM Trial of Xowna for coronary microvascular dysfunction. The FREEDOM trial enrolled approximately one-third of the targeted 105 patients, and at this rate, more than four years would likely be required to reach the primary endpoint follow-up at six months post-treatment for all subjects.

BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the H.C. Wainwright Global Investment Conference being held both virtually and in-person at the Fontainebleau Miami Beach Hotel in Miami, FL on May 23-26, 2022.